Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

Drug Discovery Today

Volumn 12, Issue 21-22, 2007, Pages 898-910

  Desjarlais, John R ^a   Lazar, Greg A ^a   Zhukovsky, Eugene A ^a   Chu, Seung Y ^a  

^a Xencor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD 30 ANTIBODY; CD20 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; GD 2 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; HEMATOPOIETIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LARGE CELL LYMPHOMA; MACROPHAGE; MONOCYTE; NEUROBLASTOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTOSIS; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOKINES; HUMANS; IMMUNE SYSTEM; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, IGG;

EID: 35748949531     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.08.009     Document Type: Review

References (97)

1. Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol. Oncol. Clin. North Am. 20 (2006) 585-612
2. Nimmerjahn F., and Ravetch J.V. Fcgamma receptors: old friends and new family members. Immunity 24 (2006) 19-28
3. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
4. Ernst L.K., et al. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J. Mol. Med. 80 (2002) 248-257
5. Kashii Y., et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 163 (1999) 5358-5366
6. Boruchov A.M., et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115 (2005) 2914-2923
7. Michon J.M., et al. In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br. J. Haematol. 100 (1998) 550-556
8. Pricop L., et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J. Immunol. 166 (2001) 531-537
9. Schakel K., et al. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28 (1998) 4084-4093
10. Chuang F.Y., et al. Convergence of Fc gamma receptor IIA and Fc gamma receptor IIIB signaling pathways in human neutrophils. J. Immunol. 164 (2000) 350-360
11. Scott-Zaki P., et al. Neutrophil chemotaxis and superoxide production are induced by cross-linking FcgammaRII receptors. Cell Immunol. 201 (2000) 89-93
12. Selenko N., et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. J. Clin. Immunol. 22 (2002) 124-130
13. Hunter S., et al. Inhibition of Fcgamma receptor-mediated phagocytosis by a nonphagocytic Fc gamma receptor. Blood 91 (1998) 1762-1768
14. Liu Y., et al. Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes. J. Leukoc. Biol. 77 (2005) 767-776
15. van Mirre E., et al. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgammaRII (CD32), is stable over time and unaffected by cytokines. Blood 108 (2006) 584-590
16. Dhodapkar K.M., et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2910-2915
17. Su K., et al. Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178 (2007) 3272-3280
18. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004) 11-22
19. Mechetina L.V., et al. Identification of CD16-2, a novel mouse receptor homologous to CD16/Fc gamma RIII. Immunogenetics 54 (2002) 463-468
20. Nimmerjahn F., et al. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23 (2005) 41-51
21. Takai T., et al. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994) 519-529
22. Clynes R., et al. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 652-656
23. Clynes R.A., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
24. Uchida J., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199 (2004) 1659-1669
25. Hamaguchi Y., et al. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203 (2006) 743-753
26. Herlyn D., and Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 4761-4765
27. Isaacs J.D., et al. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J. Immunol. 161 (1998) 3862-3869
28. Steplewski Z., et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4852-4856
29. Zeng Y., et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol. Immunol. 42 (2005) 1311-1319
30. Hernandez-Ilizaliturri F.J., et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin. Cancer Res. 9 16 Pt 1 (2003) 5866-5873
31. McEarchern J.A., et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109 (2007) 1185-1192
32. Eisenbeis C.F., et al. Combination immunotherapy of B cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin. Cancer Res. 10 18 Pt 1 (2004) 6101-6110
33. Dyall R., et al. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29 (1999) 30-37
34. Wolpoe M.E., et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 171 (2003) 2161-2169
35. Lehrnbecher T., et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 94 (1999) 4220-4232
36. Lehrnbecher T.L., et al. Variant genotypes of FcgammaRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood 95 (2000) 2386-2390
37. Karassa F.B., et al. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed. Pharmacother. 58 (2004) 286-291
38. Sanders L.A., et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect. Immun. 63 (1995) 73-81
39. Cartron G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
40. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
41. Ferrara C., et al. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281 (2006) 5032-5036
42. Okazaki A., et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 336 (2004) 1239-1249
43. Dall'Ozzo S., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64 (2004) 4664-4669
44. Musolino A., et al. Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer. AACR Annual Meeting (2007) Abstract 4188
45. Cheung N.K., et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 24 (2006) 2885-2890
46. Kono H., et al. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14 (2005) 2881-2892
47. Li X., et al. A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 48 (2003) 3242-3252
48. Weng W.K., and Levy R. Genetic Polymorphism of the Inhibitory IgG Fc Receptor Fc gamma RIIb is not associated with clinical outcome of Rituximab treated follicular lymphoma patients. ASH Annual Meeting (2005) Abstract 2430
49. Albertsson P.A., et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24 (2003) 603-609
50. Arnould L., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br. J. Cancer 94 (2006) 259-267
51. Robertson M.J. Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 71 (2002) 173-183
52. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002) 549-555
53. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
54. Vicari A.P., et al. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12 (2002) 33-42
55. Guiducci C., et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65 (2005) 3437-3446
56. Masuda K., et al. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. (2007)
57. Chang C.C., et al. HLA class I defects in malignant lesions: what have we learned?. Keio J. Med. 52 (2003) 220-229
58. Marincola F.M., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74 (2000) 181-273
59. Allan, B. et al. Applied Molecular Evolution. Variant Fc regions, PCT/US2006/025276
60. Hansen, G. et al. Diversa/Medarex. Altered antibody Fc regions and uses thereof, PCT/US2006/011048
61. Lazar G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4005-4010
62. Shields R.L., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 (2001) 6591-6604
63. Stavenhagen, J. et al. Macrogenics. Identification and engineering of antibodies with variant Fc regions and methods of using same, USSN 10/902,588
64. Armour K.L., et al. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol. Immunol. 40 (2003) 585-593
65. Umana P., et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17 (1999) 176-180
66. Yamane-Ohnuki N., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87 (2004) 614-622
67. Cox K.M., et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat. Biotechnol. 24 (2006) 1591-1597
68. Li H., et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24 (2006) 210-215
69. Nechansky A., et al. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol. Immunol. 44 (2007) 1815-1817
70. Kaneko Y., et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
71. Kanda Y., et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (2007) 104-118
72. Shinkawa T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
73. Drescher B., et al. Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity. Immunology 110 (2003) 335-340
74. Edberg J.C., and Kimberly R.P. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J. Immunol. 159 (1997) 3849-3857
75. Siberil S., et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin. Immunol. 118 (2006) 170-179
76. Godau J., et al. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173 (2004) 3437-3445
77. Konrad S., et al. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br. J. Haematol. 134 (2006) 345-347
78. Cragg M.S., and Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004) 2738-2743
79. Di Gaetano N., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003) 1581-1587
80. Hamaguchi Y., et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174 (2005) 4389-4399
81. Bannerji R., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J. Clin. Oncol. 21 (2003) 1466-1471
82. Treon S.P., et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B cell malignancies. J. Immunother. 24 (2001) 263-271
83. Weng W.K., and Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98 (2001) 1352-1357
84. Idusogie E.E., et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166 (2001) 2571-2575
85. Dall'Acqua W.F., et al. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177 (2006) 1129-1138
86. Boissonnas A., et al. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204 (2007) 345-356
87. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
88. Cioca D.P., et al. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells. J. Immunother. 29 (2006) 41-52
89. Dhodapkar K.M., et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195 (2002) 125-133
90. Groh V., et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6461-6466
91. Kalergis A.M., and Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195 (2002) 1653-1659
92. Crea, R. et al. Bioren. Method of producing human IgG antibodies with enhanced effector functions, PCT/IB2006/001030
93. Nagarajan S., et al. Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells. J. Biol. Chem. 270 (1995) 25762-25770
94. Bredius R.G., et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 83 (1994) 624-630
95. Farag S.S., et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B cell chronic lymphocytic leukemia. Blood 103 (2004) 1472-1474
96. Weng W.K., et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22 (2004) 4717-4724
97. Kim D.H., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B cell lymphoma. Blood 108 (2006) 2720-2725